IXSB.F Stock Overview

A development stage company, engages in the commercialization of monoclonal antibodies based on its Dynamic Cross Linking (DXL) technology. More details

IXSB.F fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Shares are highly illiquid

Does not have a meaningful market cap ($154)

Latest financial reports are more than a year old

My Notes

Capture your thoughts, links and company narrative

InNexus Biotechnology, Inc. Competitors

DermTech

OTCPK:DMTK.Q

US$3.5k

Genocea Biosciences

OTCPK:GNCA.Q

US$5.9k

eFFECTOR Therapeutics

OTCPK:EFTR

US$940.0

Juva Life

OTCPK:JUVA.F

US$164.0

Price History & Performance

Summary of share price highs, lows and changes for InNexus Biotechnology
Historical stock prices
Current Share Price	US$0.000001
52 Week High	US$0.000001
52 Week Low	US$0.000001
Beta	0
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	0%
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	IXSB.F	US Biotechs	US Market
7D	0%	1.9%	0.7%
1Y	n/a	-6.6%	23.9%

Return vs Industry: Insufficient data to determine how IXSB.F performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how IXSB.F performed against the US Market.

Price Volatility

Is IXSB.F's price volatile compared to industry and market?
IXSB.F volatility
IXSB.F Average Weekly Movement	n/a
Biotechs Industry Average Movement	11.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	18.7%
10% least volatile stocks in US Market	3.1%

Stable Share Price: IXSB.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine IXSB.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	n/a	n/a

InNexus Biotechnology, Inc., a development stage company, engages in the commercialization of monoclonal antibodies based on its Dynamic Cross Linking (DXL) technology. Its DXL technology seeks to improve the therapeutic potency of existing monoclonal antibody products by increasing the binding to target antigen, enhancing antibody effector functions, and installing new properties into antibodies. The company’s products in pipeline include DXL625, a monoclonal antibody in late stage pre-clinical development produced with enhanced binding kinetics and effector functions for the treatment of B cell non-Hodgkins lymphoma (NHL) and DXLr120, a recombinant DXL anti-CD20 antibody being developed for the treatment of B cell NHL cancer; DXL702, a monoclonal antibody being developed for the treatment of metastatic breast cancer; and DXL1218, which targets an antigen designated epidermal growth factor receptor that is over expressed in metastatic colorectal cancer and in squamous cell carcinomas of the head and neck.

InNexus Biotechnology, Inc. Fundamentals Summary

How do InNexus Biotechnology's earnings and revenue compare to its market cap?
IXSB.F fundamental statistics
Market cap	US$154.00
Earnings (TTM)	-US$2.99m
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is IXSB.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IXSB.F income statement (TTM)
Revenue	CA$0
Cost of Revenue	CA$0
Gross Profit	CA$0
Other Expenses	CA$4.28m
Earnings	-CA$4.28m

Last Reported Earnings

Mar 31, 2011

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did IXSB.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/07 07:05
End of Day Share Price	2024/11/07 00:00
Earnings	2011/03/31
Annual Earnings	2010/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

InNexus Biotechnology, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
David Dean	Cormark Securities Inc.